NCT07192341Recruiting
Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Effect of Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Source: ClinicalTrials.gov · Last updated 30 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- First submitted
- 17 Sept 2025
- Start date
- 27 Sept 2025
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Kafrelsheikh University
- Diseases
- Heart failure
- NCT number
- NCT07192341
What you commit to
- Study type: Interventional
- Planned participants: 220
- From 27 Sept 2025 to the primary completion date, 1 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Serious adverse drug reactions or serious complications over the course of treatment.
Other illness
- Severe pulmonary hypertension.
- Malignant arrhythmia.
- Malignant tumor.
- Known history of hereditary or primary angioedema.
Lab values
- Severe hepatic \[alanine aminotransferase (ALT) \>120 U/L\] and renal insufficiency \[estimated glomerular filtration rate (eGFR) \<30 mL/min\].
- Serum potassium \>5.3 mmol/L.
Other
- Hemodynamic instability.
- Use of a circulatory auxiliary circulation device.
- Blood pressure \<100/60 mmHg.
Who the study is looking for
- Age ≥ 18 years old.
- Both sexes.
- Patients with a history of prosthetic heart valves.
- Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kafrelsheikh University Coordinator of this site? Confirm its status | Kafr ash Shaykh | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.